Analysts expect ArQule, Inc. (NASDAQ:ARQL) to announce ($0.12) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ArQule’s earnings. ArQule posted earnings of ($0.08) per share during the same quarter last year, which would suggest a negative year over year growth rate of 50%. The business is expected to issue its next earnings report on Monday, November 6th.

On average, analysts expect that ArQule will report full year earnings of ($0.44) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post earnings of ($0.40) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for ArQule.

ArQule (NASDAQ:ARQL) last released its earnings results on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. During the same period last year, the company earned ($0.07) earnings per share.

Several equities research analysts recently commented on ARQL shares. Zacks Investment Research upgraded shares of ArQule from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Thursday, August 10th. ValuEngine lowered shares of ArQule from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp increased its stake in ArQule by 0.9% in the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 1,385 shares during the period. Curbstone Financial Management Corp increased its stake in ArQule by 100.0% in the third quarter. Curbstone Financial Management Corp now owns 104,572 shares of the biotechnology company’s stock valued at $116,000 after purchasing an additional 52,286 shares during the period. Finally, First Eagle Investment Management LLC increased its stake in ArQule by 8.6% in the second quarter. First Eagle Investment Management LLC now owns 11,847,575 shares of the biotechnology company’s stock valued at $14,691,000 after purchasing an additional 934,842 shares during the period. Institutional investors own 61.03% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/10/arqule-inc-arql-expected-to-post-earnings-of-0-12-per-share.html.

ArQule (NASDAQ:ARQL) traded down 4.46% during trading on Friday, hitting $1.07. The company had a trading volume of 98,149 shares. ArQule has a 52-week low of $0.92 and a 52-week high of $1.68. The firm’s 50 day moving average is $1.12 and its 200-day moving average is $1.12. The stock’s market capitalization is $76.15 million.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Get a free copy of the Zacks research report on ArQule (ARQL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related stocks with our FREE daily email newsletter.